Healthcare Analysts discuss Amgen’s (AMGN) Late-Stage Pipeline In The Rare Autoimmune Disease Arena on an Analyst/Industry conference call to be held on March 7.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen (NASDAQ:AMGN) Enters Late-Stage Testing on Weight Loss Drug
- Amgen’s Strategic Growth Potential Bolstered by Promising MariTide Phase III Trials
- Amgen price target raised to $294 from $275 at BofA
- S&P 500 (SPX) Dives as Trump’s Trade War Heats Up
- Amgen, AstraZeneca announce results from Phase 3 WAYPOINT trial on tezspire